Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial
- Department for International Development
- Congo (Democratic Republic) and Congo
- Document Type:
- Journal Article
- Priotto, G., Kasparian, S., Mutombo, W., Ngouama, D., Ghorashian, S. Arnold, U., Ghabri, S., Baudin, E., Buard, V., Kazadi-Kyanza, S., Ilunga, M., Mutangala, W., Schmid, C., Karunakara, U., Torreele, E., Kande, V., and Pohlig, G.
Background: Human African trypanosomiasis (HAT; sleeping sickness) caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients with second-stage disease are toxic, ineffective, or impractical. We assessed the efficacy and safety of nifurtimox-eflornithine combination therapy (NECT) for second-stage disease compared with the standard eflornithine regimen. Methods: A multicentre, randomised, open-label, active control, phase III, non-inferiority trial was done at four HAT treatment centres in the Republic of the Congo and the Democratic Republic of the Congo. Patients aged 15 years or older with confirmed second-stage T b gambiense infection were randomly assigned by computer-generated randomisation sequence to receive intravenous eflornithine (400 mg/kg per day, every 6 h; n=144) for 14 days or intravenous eflornithine (400 mg/kg per day, every 12 h) for 7 days with oral nifurtimox (15 mg/kg per day, every 8 h) for 10 days (NECT; n=143). The primary endpoint was cure (defined as absence of trypanosomes in body fluids and a leucocyte count ≤20 cells per μL) 18 months after treatment. Efficacy analyses were done in the intention-to-treat (ITT), modified ITT, and per-protocol (PP) populations. The non-inferiority margin for the difference in cure rates was defined as 10%. This study is registered with ClinicalTrials.gov, number NCT00146627. Findings: One patient from the eflornithine group absconded after receiving the first dose, without any type of assessment done, and was excluded from all analyses. In the ITT population, 131 (91•6%) of 143 patients assigned to eflornithine and 138 (96•5%) of 143 patients assigned to NECT were cured at 18 months (difference −4•9%, one-sided 95% CI −0•3; p
Priotto, G.; Kasparian, S.; Mutombo, W.; Ngouama, D.; Ghorashian, S.; Arnold, U.; Ghabri, S.; Baudin, E.; Buard, V.; Kazadi-Kyanza, S.; Ilunga, M.; Mutangala, W.; Schmid, C.; Karunakara, U.; Torreele, E.; Kande, V.; Pohlig, G. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet (2009) 374 (9683) 56-64. [DOI: 10.1016/S0140-6736(09)61117-X]
Document Type: Journal Article
Authors: Priotto, G. Kasparian, S. Mutombo, W. Ngouama, D. Ghorashian, S. Arnold, U. Ghabri, S. Baudin, E. Buard, V. Kazadi-Kyanza, S. Ilunga, M. Mutangala, W. Schmid, C. Karunakara, U. Torreele, E. Kande, V. Pohlig, G.